Portrazza (necitumumab) is a targeted anticancer medication used to treat non-small cell lung cancer (NSCLC). More specifically, it blocks a protein called epidermal growth factor receptor (EGFR) to prevent the growth and spread of cancer cells. Portrazza (necitumumab) is given intravenously (IV) by a healthcare provider at their office or an infusion center. Though it’s still approved by the FDA, Portrazza (necitumumab) isn't a recommended medication in the United States any longer because there are other treatments that work just as well or better and that don’t have as many side effects.
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
American Cancer Society. (2023). What is lung cancer?
Eli Lilly and Company. (2017). Portrazza - necitumumab solution [package insert]. DailyMed.
Lacouture, M. E., et al. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer.
National Cancer Institute. (n.d.). Epidermal growth factor receptor.
National Cancer Institute. (n.d.). Port.
National Cancer Institute. (2022). Targeted therapy to treat cancer.
National Comprehensive Cancer Network. (2023). Metastatic non-small cell lung cancer.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.